Moderna: BARDA funding for phase 3 H5N1 vaccine trial terminated
birdflustocks.com » bird flu stocks  »  Moderna: BARDA funding for phase 3 H5N1 vaccine trial terminated
Moderna: BARDA funding for phase 3 H5N1 vaccine trial terminated

The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines.